Refoxy Pharmaceuticals

Refoxy Pharmaceuticals is a German biotech startup pioneering a novel approach to aging-associated diseases by targeting FOXO3, a master regulator of cellular health and stress response. Founded in 2018, the company is in the pre-clinical stage, developing therapies intended to treat complex, multifactorial conditions such as fibrosis and cardiovascular disease to extend healthspan. Leveraging its F.act finder discovery platform, Refoxy seeks to identify and develop small molecule activators of FOXO3, positioning itself in the growing longevity and geroscience market. The company is led by a team of scientists and entrepreneurs and operates as a private, pre-revenue entity.

F.act finder discovery platform for identifying small molecule modulators of the FOXO3 transcription factor.

Refoxy competes in the longevity biotech space, where competitors include companies developing senolytics (e.g., Unity Biotechnology), mTOR inhibitors (e.g., resTORbio), and other novel mechanisms. Its specific focus on FOXO3 small molecule activators is a niche but contested area, with both biotech and academic groups exploring similar approaches.